Skip to main content
FDCT
OTC Technology

FDCTech Restates Q1 2025 Financials, Discloses Material Weaknesses in Internal Controls

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Technology
Sentiment info
Negative
Importance info
9
Price
$0.061
Mkt Cap
$25.808M
52W Low
$0.001
52W High
$0.115
52W Position
Off High info
47% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

Summary

FDCTech restated its Q1 2025 financials and revealed material weaknesses in internal controls, following a non-reliance notice and concurrent restatements for prior fiscal years, alongside ongoing legal challenges.


Key Events · Corporate Governance and Compliance · FDCT

  • Financial Restatement

    Restated Q1 2025 financial statements due to errors, increasing Q1 2025 net income before taxes by $209,574 to $314,122. This follows a non-reliance notice issued on June 3, 2026, and concurrent restatements for fiscal years 2024 and 2025.

  • Material Weaknesses in Internal Controls

    Identified material weaknesses in internal controls over financial reporting, including issues with subscription receivable classification, stock issuance tracking, and restricted cash presentation. Remediation measures are being implemented.

  • Balance Sheet Reclassifications

    Reclassified an $8.2 million subscription receivable from current assets to a contra-equity account and $17.45 million of client funds to restricted cash with a corresponding client funds payable liability.

  • Unrecorded Shares Recognized

    Recognized 500,000 common shares issued in October 2021 that were previously unrecorded by the company's transfer agent.


Analysis · FDCT · Technology

FDCTech has filed an amended quarterly report for Q1 2025, restating its financial statements due to errors and disclosing material weaknesses in internal controls. This follows a non-reliance notice issued on June 3, 2026, and concurrent restatements for fiscal years 2024 and 2025. The restatement includes significant reclassifications and corrections, such as an $8.2 million subscription receivable reclassified to contra-equity and $17.45 million in client funds reclassified to restricted cash. The company also faces multiple ongoing legal proceedings, including a $1.02 million claim against it and an appeal against a €419,997 administrative penalty. While the restatement did result in a higher net income for Q1 2025, the underlying issues with financial reporting and internal controls, coupled with the legal risks, present a significant concern for investors. The company is implementing remediation measures and plans an uplisting, but these efforts are overshadowed by the severity of the disclosed weaknesses.

At the time of this filing, FDCT was trading at $0.06 on OTC in the Technology sector, with a market capitalization of approximately $25.8M. The 52-week trading range was $0.00 to $0.12. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

FDCT - Latest Insights

FDCT
Jun 23, 2026, 4:38 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.034
Real-time Price: $0.030 info
Change: Reverse Stock Split info
Market Cap: $12.693M info
FDCT
Jun 23, 2026, 4:37 PM EDT
Filing Type: 10-K/A
Importance Score:
8
Price at Filing: $0.034
Real-time Price: $0.030 info
Change: Reverse Stock Split info
Market Cap: $12.693M info
FDCT
Jun 08, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.061
Real-time Price: $0.030 info
Change: Reverse Stock Split info
Market Cap: $12.693M info
FDCT
Jun 08, 2026, 5:30 PM EDT
Filing Type: 10-Q/A
Importance Score:
9
Price at Filing: $0.061
Real-time Price: $0.030 info
Change: Reverse Stock Split info
Market Cap: $12.693M info
FDCT
Jun 08, 2026, 5:29 PM EDT
Filing Type: 10-K/A
Importance Score:
9
Price at Filing: $0.061
Real-time Price: $0.030 info
Change: Reverse Stock Split info
Market Cap: $12.693M info